-

07:32:34 PM

CNTX Stock News

CNTX - Context Therapeutics Inc

03/22/23 5:08 PM

Nasdaq : CNTX

earningslow float

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Context Therapeutics Inc. (“Context” or the

RHEA-AI

neutral

03/15/23 7:30 AM

Nasdaq : CNTX

low float

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors,

RHEA-AI

neutral

02/06/23 7:30 AM

Nasdaq : CNTX

clinical triallow float

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a company developing novel treatments for

RHEA-AI

neutral

01/31/23 7:30 AM

Nasdaq : CNTX

fda approvallow float

Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

RHEA-AI

very positive

01/09/23 7:30 AM

Nasdaq : CNTX

low float

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6 PHILADELPHIA and BASEL, Switzerland, Jan.

RHEA-AI

neutral

01/04/23 7:30 AM

Nasdaq : CNTX

low float

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in 2023 ELONA breast cancer trial open and enrolled first patient PHILADELPHIA, Jan. 04, 2023 (GLOBE

RHEA-AI

positive

12/08/22 7:30 AM

Nasdaq : CNTX

clinical triallow float

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Data presented at San Antonio Breast Cancer Symposium ® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in ongoing Phase 2 endometrial cancer trial PHILADELPHIA, Dec.

RHEA-AI

positive

11/29/22 7:30 AM

Nasdaq : CNTX

low float

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a

RHEA-AI

neutral

11/09/22 4:14 PM

Nasdaq : CNTX

earningslow float

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR + recurrent endometrial cancer ONA-XR continues to exhibit favorable

RHEA-AI

neutral

09/27/22 7:30 AM

Nasdaq : CNTX

low float

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing

RHEA-AI

positive

CNTX Data

IndustryPharmaceutical Preparation Manufacturing
Websitecontexttherapeutics.com
Security nameContext Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees7
Address3675 Market Street
Address2Suite 200
StatePennsylvania
CityPhiladelphia
Zip19104
CountryUnited States
Phone12672257416

About Context Therapeutics Inc

Context Therapeutics Inc., is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The Company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is headquartered in Philadelphia, PA.